209 related articles for article (PubMed ID: 22492419)
1. [Interactions of proton pump inhibitors with oral bisphosphonates and fracture risk].
Bartl R; von Tresckow E
Dtsch Med Wochenschr; 2012 Apr; 137(15):804-5. PubMed ID: 22492419
[No Abstract] [Full Text] [Related]
2. In brief: duration of use of bisphosphonates.
Med Lett Drugs Ther; 2011 Oct; 53(1374):77. PubMed ID: 21959355
[No Abstract] [Full Text] [Related]
3. Inverse association between duration of use of acid-suppressive medications and fracture risk.
de Vries F
Arch Intern Med; 2011 Jun; 171(11):1044; author reply 1044. PubMed ID: 21670381
[No Abstract] [Full Text] [Related]
4. Opportunities to decrease inappropriate uses of proton pump inhibitors: Comment on "Proton pump inhibitor use and the antifracture efficacy of alendronate".
Katz MH
Arch Intern Med; 2011 Jun; 171(11):1004-5. PubMed ID: 21321289
[No Abstract] [Full Text] [Related]
5. [Calcium pros and cons: long term use of bisphosphonates. Bisphosphonates should be used for postmenopausal osteoporosis for a long term].
Soen S
Clin Calcium; 2011 Oct; 21(10):1543-6. PubMed ID: 21960242
[TBL] [Abstract][Full Text] [Related]
6. [Progress and problems in oral bisphosphonate].
Takeuchi Y
Clin Calcium; 2014 Jan; 24(1):27-33. PubMed ID: 24369277
[TBL] [Abstract][Full Text] [Related]
7. Proton pump inhibitor use and the antifracture efficacy of alendronate.
Abrahamsen B; Eiken P; Eastell R
Arch Intern Med; 2011 Jun; 171(11):998-1004. PubMed ID: 21321287
[TBL] [Abstract][Full Text] [Related]
8. [Atypical subtrochanteric fractures after long-term bisphosphonate therapy].
Czerwiński E
Endokrynol Pol; 2011; 62 Suppl 2():42-5. PubMed ID: 22125022
[TBL] [Abstract][Full Text] [Related]
9. Oral bisphosphonates and osteonecrosis of the jaw.
Wynn RL
Gen Dent; 2007; 55(1):8-10. PubMed ID: 17333956
[No Abstract] [Full Text] [Related]
10. Oral bisphosphonates and atrial fibrillation.
Majumdar SR
BMJ; 2008 Apr; 336(7648):784-5. PubMed ID: 18334526
[TBL] [Abstract][Full Text] [Related]
11. [Bisphosphonates (BP) and osteonecrosis of the jaws; should administration of BP be discontinued at the early phase?].
Urade M
Clin Calcium; 2010 Nov; 20(11):1740-3. PubMed ID: 21066911
[No Abstract] [Full Text] [Related]
12. [Bisphosphonates (BP) and osteonecrosis of the jaws; continuous treatment with Bisphosphonates should be considered].
Mawatari T
Clin Calcium; 2010 Nov; 20(11):1743-7. PubMed ID: 21066910
[No Abstract] [Full Text] [Related]
13. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates.
de Vries F; Cooper AL; Cockle SM; van Staa TP; Cooper C
Osteoporos Int; 2009 Dec; 20(12):1989-98. PubMed ID: 19333676
[TBL] [Abstract][Full Text] [Related]
14. [Long-term use of proton pump inhibitors--really harmless?].
Haag S
Dtsch Med Wochenschr; 2013 Nov; 138(45):2319-21. PubMed ID: 24163169
[No Abstract] [Full Text] [Related]
15. Bisphosphonate-induced fractures: nature strikes back?
Aspenberg P
Acta Orthop; 2008 Aug; 79(4):459-60. PubMed ID: 18766476
[No Abstract] [Full Text] [Related]
16. Bisphosphonates and atypical femoral fractures: a time for reflection.
Compston JE
Maturitas; 2010 Jan; 65(1):3-4. PubMed ID: 19932574
[No Abstract] [Full Text] [Related]
17. Atypical subtrochanteric fractures after long-term bisphosphonate therapy.
Czerwiński E
Endokrynol Pol; 2011; 62(1):84-7. PubMed ID: 21365585
[TBL] [Abstract][Full Text] [Related]
18. Proton pump inhibitors and fractures? Beware long-term use.
Prescrire Int; 2009 Oct; 18(103):216. PubMed ID: 19885973
[No Abstract] [Full Text] [Related]
19. A once-yearly IV bisphosphonate for osteoporosis.
Med Lett Drugs Ther; 2007 Nov; 49(1273):89-90. PubMed ID: 17975523
[No Abstract] [Full Text] [Related]
20. Oral bisphosphonates and dental implants.
McLeod NM
J Oral Maxillofac Surg; 2009 Jun; 67(6):1355. PubMed ID: 19446233
[No Abstract] [Full Text] [Related]
[Next] [New Search]
